2-bromo-1-phenylethyl cyanamide | 185098-76-4

• 分子结构分类: 有机化合物 - 有机氮化合物
• 英文名称: 2-bromo-1-phenylethyl cyanamide
• 英文别名: (2-bromo-1-phenylethyl)cyanamide
• CAS: 185098-76-4
• 化学式: C₉H₉BrN₂
• 分子量: 225.088
• InChiKey: HMCCXTJFNDKNDO-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.7
• 重原子数：
  12
• 可旋转键数：
  3
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.22
• 拓扑面积：
  35.8
• 氢给体数：
  1
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  2-bromo-1-phenylethyl cyanamide 在 盐酸 、 碳酸氢钠 、 sodium carbonate 作用下， 以 乙醚 为溶剂， 生成 1-(4-Methylphenyl)sulfonyl-4-phenylimidazolidin-2-one
  参考文献：
  名称：

  Synthesis and evaluation of cytotoxic activity of novel arylsulfonylimidazolidinones

  摘要：

  Synthesis of novel arylsulfonylimidazolidinones 3 and 4 containing sulfonylurea pharmacophore and evaluation of their in vitro cytotoxicity against human cell lines were investigated. As a result, a series of 4-phenyl-1(N)-arylsulfonylimidazolidinones have been found to be the potential anticancer agent. Copyright (C) 1996 Elsevier Science Ltd

  DOI：

  10.1016/0960-894x(96)00463-5
• 作为产物：
  描述：

  苯乙烯 、 氰胺 在 N-溴代丁二酰亚胺(NBS) 作用下， 以 二氯甲烷 为溶剂， 以64%的产率得到2-bromo-1-phenylethyl cyanamide
  参考文献：
  名称：

  Synthesis and evaluation of cytotoxic activity of novel arylsulfonylimidazolidinones

  摘要：

  Synthesis of novel arylsulfonylimidazolidinones 3 and 4 containing sulfonylurea pharmacophore and evaluation of their in vitro cytotoxicity against human cell lines were investigated. As a result, a series of 4-phenyl-1(N)-arylsulfonylimidazolidinones have been found to be the potential anticancer agent. Copyright (C) 1996 Elsevier Science Ltd

  DOI：

  10.1016/0960-894x(96)00463-5

文献信息

• [EN] ARYLSULFONYLIMIDAZOLONE DERIVATIVES AS AN ANTITUMOR AGENT<br/>[FR] DERIVES D'ARYLSULFONYLIMIDAZOLINE AGISSANT EN TANT QU'AGENTS ANTI-TUMORAUX
  申请人：DONG WHA PHARM. IND. CO., LTD.

  公开号：WO1998007719A1

  公开（公告）日：1998-02-26

  (EN) The present invention relates to a novel arylsulfonylimidazolone derivative represented by formula (I) which shows a superior antineoplastic activity in contrast to the known sulfonylurea antitumor agents as well as little side effect; and its pharmaceutically acceptable salt and stereoisomer, in which --, R1 and R2 are as defined in the specification.(FR) L'invention se rapporte à un nouveau dérivé d'arylsulfonylimidazoline qui répond à la formule suivante (I) où --, R1 et R2 sont tels qu'ils sont définis dans la description, et qui possède une action antinéoplastique supérieure à celle des agents anti-tumoraux connus à base de sulfonylurée tout en ayant peu d'effets secondaires; l'invention se rapporte également à un sel pharmaceutiquement acceptable et à un stéréo-isomère dudit dérivé.

  本发明涉及一种新的芳基磺酰基咪唑酮衍生物，其化学式表示为(I)，与已知的磺酰脲类抗肿瘤药物相比，具有更优异的抗肿瘤活性和较小的副作用；以及其药学上可接受的盐和立体异构体，其中--，R1和R2如规范中所定义。
• Arylsulfonylimidazolone derivatives as an antitumor agent
  申请人：Dong Wha Pharm. Ind. Co., Ltd.

  公开号：US05929103A1

  公开（公告）日：1999-07-27

  The present invention relates to a novel arylsulfonylimidazolone derivative represented by the following formula (I) which shows a superior antineoplastic activity in contrast to the known sulfonylurea antitumor agents as well as little side effect: ##STR1## and its pharmaceutically acceptable salt and stereoisomer, in which ----, R.sub.1, and R.sub.2 are as defined in the specification.

  本发明涉及一种新型芳基磺酰基咪唑酮衍生物，其化学式如下(I)，与已知的磺酰脲类抗肿瘤药物相比具有更优异的抗肿瘤活性，且副作用小：##STR1## 以及其药学上可接受的盐和立体异构体，其中----，R.sub.1和R.sub.2在说明书中定义。
• ARYLSULFONYLIMIDAZOLONE DERIVATIVES AS AN ANTITUMOR AGENT
  申请人：DONG WHA PHARMACEUTICAL INDUSTRIAL CO. LTD.

  公开号：EP1021437B1

  公开（公告）日：2001-11-14
• Structure–activity relationship studies of novel arylsulfonylimidazolidinones for their anticancer activity
  作者：Santhosh Subramanian、Nam-Soo Kim、Pillaiyar Thanigaimalai、Vinay K. Sharma、Ki-Cheul Lee、Jong Seong Kang、Hwan-Mook Kim、Sang-Hun Jung

  DOI：10.1016/j.ejmech.2011.04.042

  日期：2011.8

  To define the SAR, a series of novel N-arylsulfonylimidazolidinone derivatives were evaluated for their in vitro anticancer activity against five human tumor cell lines, including A549, COLO205, KATO III, K562, SK-OV-3 and murine leukemia (P288D1) cell line. Among them, N-(2-chloroacetyl)-6-(2-oxo-4-phenylimidazolidin-1-ylsulfonyl)-3,4-dihydroquinoline-1(2H)-carboxamide (4m) and N-cyclohexyl-6-(2-oxo-4-phenylimidazolidin-1-ylsulfonyl)-3,4-dihydroquinoline-1(2H)-carboxamide (4n) exhibited comparable in vitro anticancer activity to doxorubicin against A549, KATO III and K562 cell lines and gave superior xenographic results against NCI-H23 and SW620 cancer cell lines. Regarding the structure activity relationship, two critical points were discovered; the steric congestion at 4-position of N-arylsulfonylimidazolidinone scaffold abolishes the activity and the bulkiness or hydrophobicity of acyl groups at 3,4-dihydroquinoline of 4, especially with carbamoyl moiety, enormously enhances the activity. (C) 2011 Elsevier Masson SAS. All rights reserved.
• US5929103A
  申请人：——

  公开号：US5929103A

  公开（公告）日：1999-07-27